Comparison Between 5-Azacytidine Treatment and Allogeneic Stem-Cell Transplantation in Elderly Patients With Advanced MDS According to Donor Availability (VidazaAllo Study)

N Kroger; K Sockel; C Wolschke; W Bethge; RF Schlenk; D Wolf; M Stadler; G Kobbe; G Wulf; G Bug; K Schafer-Eckart; C Scheid; F Nolte; J Kronke; M Stelljes; D Beelen; M Heinzelmann; D Haase; H Buchner; G Bleckert; A Giagounidis; U Platzbecker

doi:10.1200/JCO.20.02724

Comparison Between 5-Azacytidine Treatment and Allogeneic Stem-Cell Transplantation in Elderly Patients With Advanced MDS According to Donor Availability (VidazaAllo Study)

N Kroger, K Sockel, C Wolschke, W Bethge, RF Schlenk, D Wolf, M Stadler, G Kobbe, G Wulf, G Bug, K Schafer-Eckart (Co-Autor/-in), C Scheid, F Nolte, J Kronke, M Stelljes, D Beelen, M Heinzelmann, D Haase, H Buchner, G BleckertA Giagounidis, U Platzbecker

Universitätsklinik für Innere Medizin 5 - Onkologie und Hämatologie

Publikation: Beitrag in Fachzeitschrift › Originalarbeit › Begutachtung

Originalsprache	Englisch
Seiten (von - bis)	3318-+
Fachzeitschrift	JOURNAL OF CLINICAL ONCOLOGY
Jahrgang	39
Ausgabenummer	30
DOIs	https://doi.org/10.1200/JCO.20.02724
Publikationsstatus	Veröffentlicht - 2021

Zugriff auf Dokument

10.1200/JCO.20.02724

Dieses zitieren

Kroger, N., Sockel, K., Wolschke, C., Bethge, W., Schlenk, RF., Wolf, D., Stadler, M., Kobbe, G., Wulf, G., Bug, G., Schafer-Eckart, K., Scheid, C., Nolte, F., Kronke, J., Stelljes, M., Beelen, D., Heinzelmann, M., Haase, D., Buchner, H., ... Platzbecker, U. (2021). Comparison Between 5-Azacytidine Treatment and Allogeneic Stem-Cell Transplantation in Elderly Patients With Advanced MDS According to Donor Availability (VidazaAllo Study). JOURNAL OF CLINICAL ONCOLOGY , 39(30), 3318-+. https://doi.org/10.1200/JCO.20.02724

Kroger, N ; Sockel, K ; Wolschke, C et al. / Comparison Between 5-Azacytidine Treatment and Allogeneic Stem-Cell Transplantation in Elderly Patients With Advanced MDS According to Donor Availability (VidazaAllo Study). in: JOURNAL OF CLINICAL ONCOLOGY 2021 ; Jahrgang 39, Nr. 30. S. 3318-+.

@article{30d055398bda467cbc9ad6eca4857faa,

title = "Comparison Between 5-Azacytidine Treatment and Allogeneic Stem-Cell Transplantation in Elderly Patients With Advanced MDS According to Donor Availability (VidazaAllo Study)",

keywords = "ACUTE MYELOID-LEUKEMIA, RISK MYELODYSPLASTIC SYNDROMES, MALIGNANCIES WORKING PARTY, SOCIETE FRANCAISE, SCORING SYSTEM, AZACITIDINE, CHEMOTHERAPY, SUBCOMMITTEE, EFFICACY, GREFFE",

author = "N Kroger and K Sockel and C Wolschke and W Bethge and RF Schlenk and D Wolf and M Stadler and G Kobbe and G Wulf and G Bug and K Schafer-Eckart and C Scheid and F Nolte and J Kronke and M Stelljes and D Beelen and M Heinzelmann and D Haase and H Buchner and G Bleckert and A Giagounidis and U Platzbecker",

year = "2021",

doi = "10.1200/JCO.20.02724",

language = "English",

volume = "39",

pages = "3318--+",

journal = "JOURNAL OF CLINICAL ONCOLOGY ",

issn = "0732-183X",

publisher = "Lippincott Williams \& Wilkins ",

number = "30",

}

Kroger, N, Sockel, K, Wolschke, C, Bethge, W, Schlenk, RF, Wolf, D, Stadler, M, Kobbe, G, Wulf, G, Bug, G, Schafer-Eckart, K, Scheid, C, Nolte, F, Kronke, J, Stelljes, M, Beelen, D, Heinzelmann, M, Haase, D, Buchner, H, Bleckert, G, Giagounidis, A & Platzbecker, U 2021, 'Comparison Between 5-Azacytidine Treatment and Allogeneic Stem-Cell Transplantation in Elderly Patients With Advanced MDS According to Donor Availability (VidazaAllo Study)', JOURNAL OF CLINICAL ONCOLOGY , Jg. 39, Nr. 30, S. 3318-+. https://doi.org/10.1200/JCO.20.02724

Comparison Between 5-Azacytidine Treatment and Allogeneic Stem-Cell Transplantation in Elderly Patients With Advanced MDS According to Donor Availability (VidazaAllo Study). / Kroger, N; Sockel, K; Wolschke, C et al.
in: JOURNAL OF CLINICAL ONCOLOGY , Jahrgang 39, Nr. 30, 2021, S. 3318-+.

Publikation: Beitrag in Fachzeitschrift › Originalarbeit › Begutachtung

TY - JOUR

T1 - Comparison Between 5-Azacytidine Treatment and Allogeneic Stem-Cell Transplantation in Elderly Patients With Advanced MDS According to Donor Availability (VidazaAllo Study)

AU - Kroger, N

AU - Sockel, K

AU - Wolschke, C

AU - Bethge, W

AU - Schlenk, RF

AU - Wolf, D

AU - Stadler, M

AU - Kobbe, G

AU - Wulf, G

AU - Bug, G

AU - Schafer-Eckart, K

AU - Scheid, C

AU - Nolte, F

AU - Kronke, J

AU - Stelljes, M

AU - Beelen, D

AU - Heinzelmann, M

AU - Haase, D

AU - Buchner, H

AU - Bleckert, G

AU - Giagounidis, A

AU - Platzbecker, U

PY - 2021

Y1 - 2021

KW - ACUTE MYELOID-LEUKEMIA

KW - RISK MYELODYSPLASTIC SYNDROMES

KW - MALIGNANCIES WORKING PARTY

KW - SOCIETE FRANCAISE

KW - SCORING SYSTEM

KW - AZACITIDINE

KW - CHEMOTHERAPY

KW - SUBCOMMITTEE

KW - EFFICACY

KW - GREFFE

U2 - 10.1200/JCO.20.02724

DO - 10.1200/JCO.20.02724

M3 - Original Article

C2 - 34283629

SN - 0732-183X

VL - 39

SP - 3318-+

JO - JOURNAL OF CLINICAL ONCOLOGY

JF - JOURNAL OF CLINICAL ONCOLOGY

IS - 30

ER -

Kroger N, Sockel K, Wolschke C, Bethge W, Schlenk RF, Wolf D et al. Comparison Between 5-Azacytidine Treatment and Allogeneic Stem-Cell Transplantation in Elderly Patients With Advanced MDS According to Donor Availability (VidazaAllo Study). JOURNAL OF CLINICAL ONCOLOGY . 2021;39(30):3318-+. doi: 10.1200/JCO.20.02724